Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014   Veracyte, Inc. ... H. Anderson , president and chief executive officer, will present ... th Annual Healthcare Conference on Tuesday, December 2, 2014 ... . The live audio webcast and subsequent replay ... . Please connect to the website at least 15 minutes ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/24/2014)... Massachusetts (PRWEB) November 24, 2014 ... Panels ” from METTLER TOLEDO demonstrates how to ... , Power analytics and sample panel design can ... cycle chemistry and protect against corrosion and deposition. ... up a significant amount of panel space. Additionally, ...
(Date:11/24/2014)... 24, 2014 Senior Vice President, ... dynamic leadership skills, business acumen Elsevier ... information products and services, congratulates Diane Bartoli , ... and Workflow, Elsevier Clinical Solutions, for being recognized in ... Awards issue of Profiles in Diversity Journal ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3
... 6 Axelar AB today announced successful,completion of ... phase I/II,clinical trial on cancer patients with its ... inhibitor which has no effects,on the closely related ... on,patients having terminal cancer disease. The results showed ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and,innovative anti-cancer pharmaceuticals in China, announced today that ... on Monday, May 18, 2009,after the market closes ... Ren, and chief financial officer, Frank Zhigang Zhao, ...
... 5 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today ... For the first quarter of 2009, the Company reported a ... a net loss of $21.1 million, or $0.55 per share, for ... 2009 were $0.7 million compared with $1.8 million for the same ...
Cached Biology Technology:Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2Simcere Pharmaceutical Group to Announce 2009 First Quarter Earnings on Monday, May 18, 2009 2Neurocrine Biosciences Reports First Quarter 2009 Results 2Neurocrine Biosciences Reports First Quarter 2009 Results 3Neurocrine Biosciences Reports First Quarter 2009 Results 4Neurocrine Biosciences Reports First Quarter 2009 Results 5Neurocrine Biosciences Reports First Quarter 2009 Results 6Neurocrine Biosciences Reports First Quarter 2009 Results 7Neurocrine Biosciences Reports First Quarter 2009 Results 8
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
(Date:11/6/2014)... Medicine, Inc, a Baltimore-based bioinformatics company focused on ... a research collaboration with the international leader in ... CSBR). , "There are many companies utilizing advances ... TumorGraft technology is unique in a way that ... vast amounts of valuable data. Our bioinformatic analysis ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... issue of Genes & Development, Dr. Karlene Cimprich and ... structure sufficient to activate the ATR-mediated DNA damage checkpoint. ... says Dr. Cimprich. "The ability to precisely define and ... an experimental system will enable us to control, quantitative ...
... one cause of high blood pressure lies within the brain, ... forward by scientists at the University of Bristol, UK, and ... Hidefumi Waki, working in a research group led by Professor ... JAM-1 (junctional adhesion molecule-1), which is located in the walls ...
... Trek: The Next Generation," Geordi La Forge is a ... special implants in his eyes. While the Star Trek ... the 21st century may not have to wait that ... a University of Missouri-Columbia veterinary ophthalmologist, has been working ...
Cached Biology News:Blame the brain for high blood pressure 2MU researcher placing eye implants in cats to help humans see 2
... and efficient method for purification of DNA fragments ... fragments selectively absorbed in the spin column after ... room temperature for PCR product with equal volume ... DNA can be purified with a single prep ...
BlotGel application pool -see Blotters (Semi-Dry) for more info...
lid holder -see Blotters (Semi-Dry) for more info...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD45RA TAC is designed to deplete human CD45RA from samples to isolate memory CD4+ or CD8+ T cells....
Biology Products: